NewswireToday - /newswire/ -
Nottingham, United Kingdom, 2009/10/05 - Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, will be showcasing its innovative line of drug delivery solutions at booth #10E36 at CPhI Worldwide 2009, October 13-15, in Feria de Madrid, Spain.

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!

Novozymes Biopharma's range of recombinant, animal-free products and technologies are used by leading pharmaceutical and biotech organizations for applications in biomanufacturing, drug delivery and medical devices. The company's drug delivery solutions provide ISO or GMP-compliant materials for enhanced regulatory compliance and performance, with drug targeting and controlled release systems for improved local and systematic delivery. The formulation solutions also ensure stability and solubility of biotherapeutics while the technology significantly improves half-life of biotherapeutics from hours to weeks.

Peter Rosholm, Vice President, Novozymes Biopharma comments: "Our presence in the field of protein drug delivery systems is helping the biopharmaceutical industry manage the issues that it encounters on a day-to-day basis including low stability and lack of efficacy."

Novozymes Biopharma will be presenting a session "Safe Products and Technologies for the Biopharmaceutical Industry - Optimizing Your Manufacturing Process, Drug Formulation and Drug Delivery" during the show. The presentation is open to all delegates and will take place at 2.30pm at the CPhI Speaker's Corner located on the show floor, booth #10G16.

Following its success in 2008, winning the Gold Innovation Award for its novel form of hyaluronic acid HyaCare, the company is delighted to announce that it has been nominated for the 2009 CPhI innovation awards for its albufuse albumin fusion technology.

To learn more about the company's drug delivery solutions, come and join Novozymes Biopharma at booth #10E36 at CPhI 2009.

About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.

Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.